From HCV To HBV Cure


Approximately 170 million people are chronically infected with HCV and 350 million are chronically infected with HBV worldwide. It is estimated that more than one million patients die from complications related to chronic viral hepatitis, mainly HCC which is one of the most frequent cancers in many countries, especially Africa, the Middle East and Asia. HCV drug development has been impressive, and this revolution led to several direct- acting antiviral agents achieving an HCV cure after only 6- 12 weeks. This progress could theorically lead to HCV global elimination making HCV and its consequences a rarity. HBV research and development programs can learn from the HCV experience, to achieve an HBV functional or sterilizing cure. This review will summarize key steps which have been realized for an HCV cure, and discuss the next steps to achieve for an HCV elimination. And also, how this HCV revolution has inspired scientists and clinicians to achieve the same for HBV.



HCV elimination , direct-acting antivirals , HBV cure , ccc DNA , capsid inhibitors

About Speaker


Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology


City: Atlanta

Institution: Emory University


Biography of Raymond SCHINAZI

Dr. Raymond F. Schinaziis the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University and co-Director of the HIV Cure Scientific Working Group for the NIH- sponsored Emory University Center for AIDS Research (CFAR). He has authored over 550 peer-reviewed papers and 7 books and holds over 100 issued US patents, which have resulted in 17 New Drug Applications (NDA). A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV, HBV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine), LdT (telbivudine), and sofosbuvir (Sovaldi), which are all approved by the US FDA and the EMEA. He is a Charter Fellow of the National Academy of Inventors. More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented. Dr. Schinazi is the recipient of numerous awards including the 2015 William S. Middleton Award from the Department of Veterans Affairs, he is the recipient of the 2014 Distinguished Scientific Achievement Award from the American Liver Foundation, 2016 Institute of Human Virology’s Lifetime Achievement Award for Public Service, 2016 Scrip Lifetime Achievement Award, State of the Art Award from the 2017 Paris Hepatology Conference, and 2017 Excellence Prize from Journées Québécoises, McGill University. He serves as a Senior Advisor for the International Coalition to Eliminate HBV (ICE-HBV) and as an Affiliated Professor of the Institut Pasteur in Paris, France. He is also a Fellow of the American Society of Microbiology Dr. Schinazi is internationally recognized as one of the most influential persons in the life science sector.

View more